The cholesterol-lowering drug is part of a suite of medicines that also includes MariTide and that Amgen Chief Medical ...

Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...

Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...

By Deena Beasley (Reuters) -Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events ...

In March 2015, Amgen was preparing to launch Repatha, a new molecule that had demonstrated a remarkable ability to treat high cholesterol. The global brand team lead, Alex Shamoun, responsible for the ...

Amgen’s Repatha was heralded recently in the media, generating headlines like "New Drug Prevents Heart Attacks in High-Risk Patients." But the company's stock then fell. Who should we believe and why?

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a cholesterol-lowering therapy, at a significantly reduced ...

(RTTNews) - Amgen Inc. (AMGN) on Thursday announced positive results form the Phase 3 VESALIUS-CV study of Repatha in adults with high cardiovascular risk without prior heart attack or stroke. The ...

In March 2015, Amgen is preparing for the launch of Repatha, a new molecule that has demonstrated a remarkable ability to treat high cholesterol. Through a series of clinical trials, Amgen has proven ...